These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 17349016)
1. Vasoactive intestinal polypeptide enhances oral tolerance by regulating both cellular and humoral immune responses. Wang Y; Mei Y; Bao S; Xu L Clin Exp Immunol; 2007 Apr; 148(1):178-87. PubMed ID: 17349016 [TBL] [Abstract][Full Text] [Related]
2. VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis. Yadav M; Huang MC; Goetzl EJ Cell Immunol; 2011; 267(2):124-32. PubMed ID: 21295288 [TBL] [Abstract][Full Text] [Related]
3. Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin. Huibregtse IL; Snoeck V; de Creus A; Braat H; De Jong EC; Van Deventer SJ; Rottiers P Gastroenterology; 2007 Aug; 133(2):517-28. PubMed ID: 17681173 [TBL] [Abstract][Full Text] [Related]
4. VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production. Kojima M; Ito T; Oono T; Hisano T; Igarashi H; Arita Y; Kawabe K; Coy DH; Jensen RT; Nawata H Pancreas; 2005 Jan; 30(1):62-70. PubMed ID: 15632701 [TBL] [Abstract][Full Text] [Related]
5. Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells. Delgado M; Robledo G; Rueda B; Varela N; O'Valle F; Hernandez-Cortes P; Caro M; Orozco G; Gonzalez-Rey E; Martin J Arthritis Rheum; 2008 Apr; 58(4):1010-9. PubMed ID: 18383379 [TBL] [Abstract][Full Text] [Related]
6. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation. Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009 [TBL] [Abstract][Full Text] [Related]
7. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary. Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238 [TBL] [Abstract][Full Text] [Related]
8. Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor. Voice JK; Dorsam G; Lee H; Kong Y; Goetzl EJ FASEB J; 2001 Nov; 15(13):2489-96. PubMed ID: 11689474 [TBL] [Abstract][Full Text] [Related]
9. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. Voice JK; Grinninger C; Kong Y; Bangale Y; Paul S; Goetzl EJ J Immunol; 2003 Jan; 170(1):308-14. PubMed ID: 12496414 [TBL] [Abstract][Full Text] [Related]
10. Hypersensitivity and oral tolerance in the absence of a secretory immune system. Karlsson MR; Johansen FE; Kahu H; Macpherson A; Brandtzaeg P Allergy; 2010 May; 65(5):561-70. PubMed ID: 19886928 [TBL] [Abstract][Full Text] [Related]
11. Human plasmacytoid dendritic cell function: inhibition of IFN-alpha secretion and modulation of immune phenotype by vasoactive intestinal peptide. Fabricius D; O'Dorisio MS; Blackwell S; Jahrsdörfer B J Immunol; 2006 Nov; 177(9):5920-7. PubMed ID: 17056516 [TBL] [Abstract][Full Text] [Related]
12. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells. Delgado M; Reduta A; Sharma V; Ganea D J Leukoc Biol; 2004 Jun; 75(6):1122-30. PubMed ID: 15020654 [TBL] [Abstract][Full Text] [Related]
13. Alterations of vasoactive intestinal polypeptide receptors in allergic rhinitis. Kim DH; Park IH; Cho JS; Lee YM; Choi H; Lee HM Am J Rhinol Allergy; 2011; 25(1):e44-7. PubMed ID: 21711977 [TBL] [Abstract][Full Text] [Related]
14. Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis. Sun W; Hong J; Zang YC; Liu X; Zhang JZ Int Immunol; 2006 Dec; 18(12):1691-700. PubMed ID: 17077178 [TBL] [Abstract][Full Text] [Related]
15. Allergen-specific antibody and cytokine responses, mast cell reactivity and intestinal permeability upon oral challenge of sensitized and tolerized mice. Perrier C; Thierry AC; Mercenier A; Corthésy B Clin Exp Allergy; 2010 Jan; 40(1):153-62. PubMed ID: 19689461 [TBL] [Abstract][Full Text] [Related]
16. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Juarranz Y; Gutiérrez-Cañas I; Santiago B; Carrión M; Pablos JL; Gomariz RP Arthritis Rheum; 2008 Apr; 58(4):1086-95. PubMed ID: 18383383 [TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal peptide inhibits toll-like receptor 3-induced nitric oxide production in Schwann cells and subsequent sensory neuronal cell death in vitro. Lee H; Park K; Kim JS; Lee SJ J Neurosci Res; 2009 Jan; 87(1):171-8. PubMed ID: 18683246 [TBL] [Abstract][Full Text] [Related]
18. Lack of orally induced systemic unresponsiveness in IFN-gamma knockout mice. Kweon MN; Fujihashi K; VanCott JL; Higuchi K; Yamamoto M; McGhee JR; Kiyono H J Immunol; 1998 Feb; 160(4):1687-93. PubMed ID: 9469425 [TBL] [Abstract][Full Text] [Related]
20. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]